The Redefining of Menopause as a Condition of Inflammation and Oxidation: It’s Not the Hormone but Its Home
It is well understood that hormones interact with the DNA in our a body to influence metabolic and enzymatic control. Estrogen, for example, increases activity of glutathione peroxidase and decreases inflammatory activity of NFKappaB. As we age, estrogen declines and therefore its favorable influence on these end targets is altered. By managing the decrease in glutathione created when this occurs and the increase in inflammation, we have many other natural interventions that can be used that are less invasive than hormone therapy. By understanding not only hormone testing, but being able to evaluate the environment that hormones are in, we can monitor the physiologic significance of change in estrogen. Not only do these measurements increase clinical understanding, but it widens treatment options for addressing menopausal concerns. Functional medicine is a necessary cornerstone in safe and effective hormonal management and treatment.
In this webinar you will learn:
- Th key concepts in hormone management in terms of managing a oxidative environment that contributes not only to menopausal symptoms but cancer risk.
- The common markers of oxidative stress and their relationship to estrogen metabolism, menopausal symptoms, and how to treat.
- And so much more!
More About Dr. Cheryl Burdette, ND
Cheryl Burdette, ND, is president and education director of Dunwoody Labs. She is a clinician and the director of the naturopathic
residency program at Progressive Medical Centers, which is one the largest integrative clinics in the country. Dr. Burdette serves
on IRBs and is a contributing author of the book Laboratory Evaluations in Molecular Medicine. Dr. Burdette lectures extensively
nationally and internationally. She graduated from Bastyr University in 2001, and she completed her residency at Cancer
Treatment Centers of America. The marriage of her laboratory directorship and clinical practice gives her a unique perspective
in functional medicine treatment and testing. Dr. Burdette is XYMOGEN’s Director of Clinical Research and Outreach.